(mer tah’ zah peen)

Apo-Mirtazapine (CAN), Auro-Mirtazapine (CAN), Ava-Mertazapine (CAN), CO Mirtazapine (CAN), Gen-Mirtazapine (CAN), Novo-Mirtazapine OD (CAN), Remeron, Remeron SolTabDNC, Sandoz-Mirtazapine (CAN)


Drug class

Antidepressant (tetracyclic)

Therapeutic Actions

Mechanism of action unknown; appears to act similarly to TCAs, which inhibit the presynaptic reuptake of the neurotransmitters norepinephrine and serotonin; anticholinergic at CNS and peripheral receptors; sedating; relation of these effects to clinical efficacy is unknown.


  • Treatment of major depressive disorder

  • Unlabeled uses: Chronic urticaria, hot flashes, drug-induced hyperhidrosis, pruritus, prevention of migraines in adults, insomnia, pruritus

Available Forms

Tablets—7.5, 15, 30, 45 mg; orally disintegrating tabletDNC—15, 30, 45 mg



Initial dose, 15 mg PO daily, as a single dose in evening. May be increased up to 45 mg/day as needed. Change dose only at intervals greater than 1–2 wk. Continue treatment for up to 6 mo for acute episodes.

  • Switching from MAOI: Allow at least 14 days between discontinuation of MAOI and beginning of mirtazapine therapy. Allow 14 days after stopping mirtazapine before starting MAOI.

Pediatric patients

Not recommended in patients younger than 18 yr.

Geriatric patients and patients with renal or hepatic impairment

Give lower doses to patients older than 60 yr; use with caution.

Jul 21, 2016 | Posted by in NURSING | Comments Off on Mirtazapine

Full access? Get Clinical Tree

Get Clinical Tree app for offline access